Updated on 2023/09/28

写真a

 
HANAJIRI Ryo
 
Organization
Nagoya University Hospital Hematology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 1

  1. 博士(医学) ( 2016.3   名古屋大学 ) 

Research Interests 7

  1. 造血幹細胞移植

  2. 血液内科学

  3. 細胞療法

  4. 免疫療法

  5. 免疫学

  6. キメラ抗原受容体

  7. CAR-T

Research Areas 4

  1. Life Science / Hematology and medical oncology

  2. Life Science / Hematology and medical oncology

  3. Life Science / General internal medicine

  4. Life Science / Immunology

Research History 2

  1. 名古屋大学医学部附属病院   血液内科   助教

    2021.4

      More details

    Country:Japan

  2. Nagoya University   Hematology and Oncology

    2019.7 - 2021.3

      More details

    Country:Japan

Professional Memberships 5

  1. 日本造血・免疫細胞療法学会

  2. 日本輸血・細胞療法学会

  3. 日本血液疾患免疫療法学会

  4. THE JAPANESE SOCIETY OF HEMATOLOGY

  5. THE JAPANESE SOCIETY OF INTERNAL MEDICINE

Awards 2

  1. 優秀演題賞

    2022.6   第11回日本血液学会東海地方会  

    葉名尻 良

  2. 研究費助成

    2022.4   2021年度堀科学芸術振興財団  

    葉名尻 良

 

Papers 11

  1. Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts. Reviewed

    Erina Takagi, Seitaro Terakura, Hidetsugu Fujigaki, Akinao Okamoto, Kotaro Miyao, Masashi Sawa, Takanobu Morishita, Tatsunori Goto, Yukiyasu Ozawa, Tetsuya Nishida, Nobuaki Fukushima, Kazutaka Ozeki, Ryo Hanajiri, Kuniaki Saito, Makoto Murata, Akihiro Tomita, Hitoshi Kiyoi

    International journal of hematology   Vol. 118 ( 4 ) page: 462 - 471   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18-75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5-15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (< 20 U/mL). Only patients older than 44 years had a negative response. Low IgM level was the only significant predictor of vaccine failure in elderly patients. When antibody response before and after the third vaccination was examined in 47 patients, antibodies increased significantly from a median of 18.3 U/mL to 312.6 U/mL (P < 0.01). The median antibody titer after the third vaccination of healthy individuals (n = 203) was 426.4 U/mL, which was comparable to that of patients (P = 0.2). The antibody titer after the third mRNA vaccination increased even in patients whose first two mRNA vaccinations failed. These findings suggest that allo-HSCT recipients should receive the mRNA vaccine regularly.

    DOI: 10.1007/s12185-023-03648-1

    Web of Science

    Scopus

    PubMed

  2. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan Reviewed

    Jo Tomoyasu, Yoshihara Satoshi, Okuyama Yoshiki, Fujii Keiko, Henzan Tomoko, Kahata Kaoru, Yamazaki Rie, Takeda Wataru, Umezawa Yoshihiro, Fukushima Kentaro, Ashida Takashi, Yamada‐Fujiwara Minami, Hanajiri Ryo, Yonetani Noboru, Tada Yuma, Shimura Yuji, Nishikii Hidekazu, Shiba Norio, Mimura Naoya, Ando Jun, Sato Takayuki, Nakashima Yasuhiro, Ikemoto Junko, Iwaki Keita, Fujiwara Shin‐ichiro, Ri Masaki, Nagamura‐Inoue Tokiko, Tanosaki Ryuji, Arai Yasuyuki

    British Journal of Haematology   Vol. 202 ( 2 ) page: 256 - 266   2023.7

     More details

    Language:English  

    For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B-cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, and their platelet counts (12.0 vs. 17.0 × 10⁴/μL; p = 0.01) and CD4/CD8 T-cell ratio (0.30 vs. 0.56; p < 0.01) in peripheral blood at apheresis were significantly lower than in the successful group. Multivariate analysis revealed that repeated bendamustine use with short washout periods prior to apheresis (odds ratio [OR], 5.52; p = 0.013 for ≥6 cycles with washout period of 3–24 months; OR, 57.09; p = 0.005 for ≥3 cycles with washout period of <3 months), low platelet counts (OR, 0.495 per 105/μL; p = 0.022) or low CD4/CD8 ratios (<one third) (OR, 3.249; p = 0.011) in peripheral blood at apheresis increased the risk of manufacturing failure. Manufacturing failure remains an obstacle to CAR-T cell therapy for DLBCL patients. Avoiding risk factors, such as repeated bendamustine administration without sufficient washout, and risk-adapted strategies may help to optimize CAR-T cell therapy for DLBCL patients.

    CiNii Research

  3. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan Reviewed

    Jo T., Yoshihara S., Okuyama Y., Fujii K., Henzan T., Kahata K., Yamazaki R., Takeda W., Umezawa Y., Fukushima K., Ashida T., Yamada-Fujiwara M., Hanajiri R., Yonetani N., Tada Y., Shimura Y., Nishikii H., Shiba N., Mimura N., Ando J., Sato T., Nakashima Y., Ikemoto J., Iwaki K., Fujiwara S.i., Ri M., Nagamura-Inoue T., Tanosaki R., Arai Y.

    British Journal of Haematology   Vol. 202 ( 2 ) page: 256 - 266   2023.7

     More details

    Language:English   Publisher:British Journal of Haematology  

    For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B-cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical factors between 30 cases that failed (7.4%) with those that succeeded (n = 378). Among the failures, the proportion of patients previously treated with bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, and their platelet counts (12.0 vs. 17.0 × 104/μL; p = 0.01) and CD4/CD8 T-cell ratio (0.30 vs. 0.56; p < 0.01) in peripheral blood at apheresis were significantly lower than in the successful group. Multivariate analysis revealed that repeated bendamustine use with short washout periods prior to apheresis (odds ratio [OR], 5.52; p = 0.013 for ≥6 cycles with washout period of 3–24 months; OR, 57.09; p = 0.005 for ≥3 cycles with washout period of <3 months), low platelet counts (OR, 0.495 per 105/μL; p = 0.022) or low CD4/CD8 ratios (<one third) (OR, 3.249; p = 0.011) in peripheral blood at apheresis increased the risk of manufacturing failure. Manufacturing failure remains an obstacle to CAR-T cell therapy for DLBCL patients. Avoiding risk factors, such as repeated bendamustine administration without sufficient washout, and risk-adapted strategies may help to optimize CAR-T cell therapy for DLBCL patients.

    DOI: 10.1111/bjh.18831

    Scopus

    PubMed

  4. Myelodysplastic syndrome with trisomy 8 presenting periodic fever and multiple MEFV gene variants outside exon 10: a case report Reviewed

    Takahashi Noriyuki, Hanajiri Ryo, Suzuki Masashi, Anan Chise, Inagaki Atsushi, Kishida Dai, Ozawa Shohei, Kohri Sho, Kamiya Nobuhide, Sato Motoki, Sato Juichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 85 ( 1 ) page: 195 - 203   2023.2

     More details

    Language:English   Publisher:Nagoya Journal of Medical Science  

    Myelodysplastic syndrome is associated with the development of autoinflammatory conditions, such as recurrent fever, polymyalgia, arthralgia, and erythema. Trisomy 8 is a common chromosomal abnormality in patients with myelodysplastic syndrome. Myelodysplastic syndrome with trisomy 8 involves autoinflammatory conditions, especially Behçet’s disease-like symptoms with intestinal mucosal damage. MEFV variants, particularly those in exon 10, are pathogenic in familial Mediterranean fever, the most common autoinflammatory disease, presenting typical symptoms such as periodic fever and pleuritis/pericarditis/ peritonitis. MEFV variants outside exon 10 are common in Japanese patients with familial Mediterranean fever and are associated with atypical symptoms, including myalgia and erythema. MEFV variants in myelodysplastic syndrome with trisomy 8 have rarely been investigated, although myelodysplastic syndrome with trisomy 8 might develop autoinflammatory conditions similar to those in familial Mediterranean fever. We encountered a 67-year-old man who had myelodysplastic syndrome with trisomy 8 and multiple MEFV variants outside exon 10. He presented with periodic fever, as well as chest/abdominal pain, myalgia, and erythema, although the symptoms did not fulfill the diagnostic criteria of familial Mediterranean fever. We discussed the possibility that these symptoms are modified by MEFV variants outside exon 10 in myelodysplastic syndrome with trisomy 8

    DOI: 10.18999/nagjms.85.1.195

    Web of Science

    Scopus

    PubMed

  5. Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy Reviewed

    JO Tomoyasu, HENZAN Tomoko, TOMIZAWA Daisuke, YOSHIHARA Satoru, KAHATA Kaoru, YAMADA-FUJIWARA Minami, OKUYAMA Yoshiki, SHIBA Norio, FUJII Keiko, UMEZAWA Yoshihiro, YAMAZAKI Rie, TAKEDA Wataru, HANAJIRI Ryo, FUKUSHIMA Kentaro, MIMURA Naoya, IKEMOTO Junko, IWAKI Keita, YONETANI Noboru, FUJIWARA Shin-ichiro, RI Masaki, NAGAMURA-INOUE Tokiko, TANOSAKI Ryuji, ARAI Yasuyuki

    Rinsho Ketsueki   Vol. 64 ( 5 ) page: 331 - 337   2023

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>The frequency of the manufacturing failure of chimeric antigen receptor (CAR)-T cell therapy in clinical practice is unknown. To clarify the current state of how likely CAR-T cell production is to succeed or fail for B-cell acute lymphoblastic leukemia (B-ALL), we analyzed cases in which the production of tisagenlecleucel was performed for patients with B-ALL at 15 facilities in Japan from October 2019 to March 2022. Total 81 patients (47 males and 34 females) were analyzed. The median age at apheresis was 13 years (1-25) with a median number of prior treatments of 4 (1-9). The numbers of patients with histories of allogeneic transplantation, inotuzumab ozogamicin, or blinatumomab treatments were 51 (63.0%), 26 (32.1%), and 37 (45.7%), respectively. The median blast percentage and CD3<sup>+</sup> cell counts in peripheral blood were 0% (0-91.5), and 611/µ<i>l</i> (35-4,210) at apheresis, and the median number of CD3<sup>+</sup> cells shipped was 2.2×10<sup>9</sup> (0.5-8.3). While cases with a history of heavy prior treatment before apheresis were included, no manufacturing failures were observed. Continuing to monitor the status of manufacturing failures is necessary as the number of B-ALL cases treated with CAR-T cell therapy increases.</p>

    DOI: 10.11406/rinketsu.64.331

    PubMed

    CiNii Research

  6. Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma Reviewed

    HANAJIRI Ryo, FURUKAWA Katsuya, NAKASHIMA Marie, USHIJIMA Yoko, SHIMADA Kazuyuki, ISHIKAWA Yuichi, TERAKURA Seitaro, MURATA Makoto, KIYOI Hitoshi

    Rinsho Ketsueki   Vol. 64 ( 3 ) page: 167 - 174   2023

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promise as treatment of relapsed or refractory B-cell malignancies. However, the clinical utility of early CAR-T monitoring within 1 month after infusion has not been elucidated. In this study, we quantitatively measured CAR-T kinetics in peripheral blood on days 2, 4, 7, 9, 11, 14, 21, and 28 post-infusion using flow cytometry and quantitative polymerase chain reaction in 13 patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) treated with tisagenlecleucel (tisa-cel). No relationships were identified between bulk CAR-T kinetics and treatment outcomes. Interestingly, the magnitude of CD4<sup>+</sup> CAR-T expansion was higher in responders than in nonresponders, while CD8<sup>+</sup> CAR-T expansion was minimal in responders. Additionally, CAR-T proliferation was more pronounced in patients with cytokine release syndrome. Our results suggest that CD4<sup>+</sup> CAR-T cellular kinetics within 1 month after CAR-T infusion may predict its efficacy after tisa-cel therapy in adult patients with DLBCL.</p>

    DOI: 10.11406/rinketsu.64.167

    PubMed

    CiNii Research

  7. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. Reviewed

    Yoshitaka Adachi, Toshiyasu Sakai, Seitaro Terakura, Takashi Shiina, Shingo Suzuki, Hiroshi Hamana, Hiroyuki Kishi, Takehiko Sasazuki, Hisashi Arase, Ryo Hanajiri, Tatsunori Goto, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi

    International journal of hematology   Vol. 115 ( 3 ) page: 371 - 381   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    Genomic deletion of donor-patient-mismatched HLA alleles in leukemic cells is a major cause of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Mismatched HLA is frequently lost as an individual allele or a whole region in HLA-class I, however, it is downregulated in HLA-class II. We hypothesized that there might be a difference in T cell recognition capacity against epitopes associated with HLA-class I and HLA-class II and consequently such allogeneic immune pressure induced HLA alterations in leukemic cells. To investigate this, we conducted in vitro experiments with T cell receptor-transduced T (TCR-T) cells. The cytotoxic activity of NY-ESO-1-specific TCR-T cells exhibited similarly against K562 cells with low HLA-A*02:01 expression. However, we demonstrated that the cytokine production against low HLA-DPB1*05:01 expression line decreased gradually from the HLA expression level approximately 2-log lower than normal expressors. Using sort-purified leukemia cells before and after HSCT, we applied the next-generation sequencing, and revealed that there were several marked downregulations of HLA-class II alleles which demonstrated consistently low expression from pre-transplantation. The marked downregulation of HLA-class II may lead to decreased antigen recognition ability of antigen-specific T cells and may be one of immune evasion mechanism associated with HLA-class II downregulation.

    DOI: 10.1007/s12185-021-03273-w

    Web of Science

    Scopus

    PubMed

  8. A Phase I Study of CD19 Chimeric Antigen Receptor-T Cells Generated By the PiggyBac Transposon Vector for Acute Lymphoblastic Leukemia

    Nishio Nobuhiro, Hanajiri Ryo, Ishikawa Yuichi, Murata Makoto, Taniguchi Rieko, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Narita Atsushi, Muramatsu Hideki, Takahashi Yoshiyuki

    BLOOD   Vol. 138   page: 3831 - +   2021.11

     More details

    Language:Japanese  

    DOI: 10.1182/blood-2021-150469

    Web of Science

  9. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Reviewed International journal

    Jakrawadee Julamanee, Seitaro Terakura, Koji Umemura, Yoshitaka Adachi, Kotaro Miyao, Shingo Okuno, Erina Takagi, Toshiyasu Sakai, Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Michael Hudecek, Peter Steinberger, Judith Leitner, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi

    Molecular therapy : the journal of the American Society of Gene Therapy   Vol. 29 ( 9 ) page: 2677 - 2690   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CELL PRESS  

    Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence of CAR-T cells is required to prevent relapse and provide long-term disease control. To improve CAR-T cell function and persistence, we developed a composite co-stimulatory domain of a B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. CD79A/CD40 incorporating CD19CAR-T cells (CD19.79a.40z) exhibited higher NF-κB and p38 activity upon CD19 antigen exposure compared with the CD28 or 4-1BB incorporating CD19CAR-T cells (CD19.28z and CD19.BBz). Notably, we found that CD19.79a.40z CAR-T cells continued to suppress CD19+ target cells throughout the co-culture assay, whereas a tendency for tumor growth was observed with CD19.28z CAR-T cells. Moreover, CD19.79a.40z CAR-T cells exhibited robust T cell proliferation after culturing with CD19+ target cells, regardless of exogenous interleukin-2. In terms of in vivo efficiency, CD19.79a.40z demonstrated superior anti-tumor activity and in vivo CAR-T cell proliferation compared with CD19.28z and CD19.BBz CD19CAR-T cells in Raji-inoculated mice. Our data demonstrate that the CD79A/CD40 co-stimulatory domain endows CAR-T cells with enhanced proliferative capacity and improved anti-tumor efficacy in a murine model.

    DOI: 10.1016/j.ymthe.2021.04.038

    Web of Science

    Scopus

    PubMed

  10. Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy Reviewed

    Hanajiri R, Sani GM, Saunders D, Hanley PJ, Chopra A, Mallal SA, Sosnovtsev SV, Cohen JI, Green KY, Bollard CM, Keller MD

    J Infect Dis   Vol. 221 ( 4 ) page: 578 - 588   2020.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/infdis/jiz491

  11. Lupus anticoagulant-hypoprothrombinemia syndrome associated with follicular lymphoma Reviewed

    Koyama D, Hanajiri R, Kanematsu T, Ito R, Yamamoto S, Imoto N, Suzuki N, Kurahashi S, Sugiura I

    Rinsho Ketsueki   Vol. 61 ( 7 ) page: 745 - 749   2020

▼display all

MISC 9

  1. CAR-T療法不応であったMCD type CD5陽性DLBCLに対してチラブルチニブが奏効した1例

    竹内 裕貴, 葉名尻 良, 牛島 洋子, 島田 和之, 石川 裕一, 後藤 尚絵, 寺倉 精太郎, 村田 誠, 冨田 章裕, 清井 仁

    臨床血液   Vol. 63 ( 8 ) page: 964 - 965   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

  2. チサゲンレクルユーセル輸注後におけるCAR-Tの体内動態と治療成績の検討

    葉名尻 良, 古川 勝也, 中島 麻梨絵, 牛島 洋子, 島田 和之, 石川 裕一, 寺倉 精太郎, 村田 誠, 清井 仁

    臨床血液   Vol. 63 ( 8 ) page: 965 - 965   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

  3. びまん性大細胞型B細胞リンパ腫を発症した1型高IgE症候群の孤発例

    鈴木 由以佳, 棚橋 華奈, 伊藤 靖敏, 葉名尻 良, 高間 寛之, 渡辺 大輔, 秋山 真志

    日本皮膚科学会雑誌   Vol. 132 ( 5 ) page: 1370 - 1370   2022.5

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    J-GLOBAL

  4. CD19 CAR-T細胞療法のための白血球アフェレーシス

    村田 誠, 岩田 哲, 竹内 裕貴, 吉山 聡一, 鈴木 奈瑠子, 佐合 健, 古川 勝也, 中島 麻梨絵, 葉名尻 良, 牛島 洋子, 島田 和之, 石川 裕一, 寺倉 精太郎, 長井 りさ, 古村 恵理, 松下 正, 清井 仁

    日本輸血細胞治療学会誌   Vol. 68 ( 2 ) page: 301 - 301   2022.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

  5. CD37CAR-T細胞のスペーサーの長さを微調整することで最適なシグナルを得ることができる(The optimal signal can be obtained by fine-tuning the spacer length of CD37CAR-T cells)

    安達 慶高, 奥野 真吾, 寺倉 精太郎, Julamanee Jakrawadee, 堺 寿保, 宮尾 康太郎, 梅村 晃史, 村瀬 篤史, 島田 和之, 葉名尻 良, 西田 徹也, 村田 誠, 清井 仁

    日本血液学会学術集会   Vol. 83回   page: OS2 - 3   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    J-GLOBAL

  6. ゲノムワイドCRISPRスクリーニングシステムを用いたCAR-T細胞の増殖を制御する遺伝子の同定(Genome-wide CRISPR-Cas9 screening to identify the genes regulating human CAR-T cells proliferation)

    安達 慶高, 寺倉 精太郎, 奥野 友介, 佐藤 好隆, 尾崎 正英, 今井 奏衣, 梅村 晃史, 堺 寿保, 葉名尻 良, 西田 徹也, 村田 誠, 清井 仁

    日本血液学会学術集会   Vol. 83回   page: PL - 6   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    J-GLOBAL

  7. 急性リンパ性白血病に対するpiggyBacトランスポゾン法によるCD19 CAR-T療法の臨床第I相試験(Phase I study of piggyBac transposon mediated CD19: CAR-T therapy for acute lymphoblastic leukemia)

    西尾 信博, 葉名尻 良, 石川 裕一, 寺倉 精太郎, 西田 徹也, 村田 誠, 濱田 太立, 西川 英里, 川島 希, 奥野 友介, 成田 敦, 村松 秀城, 高橋 義行

    日本血液学会学術集会   Vol. 83回   page: OS2 - 4   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    J-GLOBAL

  8. 抗HLA抗体の意義と治療戦略 造血幹細胞移植 造血幹細胞移植におけるHLA抗体の臨床的意義

    葉名尻 良

    MHC: Major Histocompatibility Complex   Vol. 28 ( 2 ) page: 133 - 133   2021.8

     More details

    Language:Japanese   Publisher:(一社)日本組織適合性学会  

  9. 高IgE症候群に併発したDLBCLの化学療法中に膿瘍を合併するもドレナージ術にて安全に治療可能であった1例

    葉名尻 良, 川島 直実, 牛島 洋子, 島田 和之, 石川 裕一, 寺倉 精太郎, 西田 徹也, 村田 誠, 清井 仁

    臨床血液   Vol. 62 ( 7 ) page: 859 - 859   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

▼display all

Presentations 10

  1. チサゲンレクルユーセル輸注後におけるCAR-Tの体内動態と治療成績の検討

    第11回日本血液学会東海地方会   2022.6.19 

     More details

    Event date: 2022.6

  2. 造血幹細胞移植における HLA 抗体の臨床的意義 Invited

    葉名尻 良

    第 4 回 東海北陸 HLA 研究会  2021.7.24 

     More details

    Event date: 2021.7

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  3. 高 IgE 症候群に併発した DLBCL の化学療法中に膿瘍を合併するもドレナージ術にて安全に治療可能であった 1 例

    葉名尻 良、川島 直実、牛島 洋子、島田 和之、石川 裕一、寺倉 精太郎、西田 徹也、村田 誠、清井 仁

    第10回日本血液学会東海地方会  2021.4.25 

     More details

    Event date: 2021.4

    Language:Japanese   Presentation type:Oral presentation (general)  

  4. Generation of Zika Virus-Specific T-Cells for Adoptive Immunotherapy

    Ryo Hanajiri, Michael D. Keller, Gelina M. Sani, Patrick J. Hanley, Esper G. Kallas, Catherine M. Bollard

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION  2019.3  ELSEVIER SCIENCE INC

     More details

    Event date: 2019.3

    Language:English  

  5. Quantitative Assessment of TCR Repertoire and Allo-Reactivity of Human Acute Gvhd Tissue-Infiltrating T Cells

    Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Shingo Okuno, Sonoko Kamoshita, Erina Takagi, Jakrawadee Julamanee, Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi

    BLOOD  2017.12  AMER SOC HEMATOLOGY

     More details

    Event date: 2017.12

    Language:English  

    0

  6. The Synergistic T-Cell Signal By CD79A/CD40 Costimulatory Endodomain Enhances CD19 Chimeric Antigen Receptor T-Cell Proliferation and Survival

    Jakrawadee Julamanee, Seitaro Terakura, Reona Sakemura, Kotaro Miyao, Shingo Okuno, Sonoko Kamoshita, Erina Takagi, Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Tetsuya Nishida, Makoto Murata, Hitoshi Kiyoi

    BLOOD  2017.12  AMER SOC HEMATOLOGY

     More details

    Event date: 2017.12

    Language:English  

    0

  7. 当院における限局期精巣原発悪性リンパ腫の臨床的検討

    野口瑛美, 岡元るみ子, 葉名尻良, 永田安伸, 下山達, 佐々木栄作, 小室泰司, 前田義治, 比島恒和, 佐々木常雄, 佐々木常雄

    日本臨床腫瘍学会学術集会プログラム・抄録集  2009 

     More details

    Event date: 2009

  8. 臍帯血移植後再発したimatinib抵抗性慢性骨髄性白血病の急性転化に対するdasatinibと化学療法の併用療法

    森甚一, 大橋一輝, 澤田武志, 葉名尻良, 菊池拓, 永田安伸, 大西千恵, 田岡謙一, 若林志穂子, 小林武, 山下卓也, 秋山秀樹, 坂巻壽

    臨床血液  2009  (一社)日本血液学会-東京事務局

     More details

    Event date: 2009

    Language:Japanese  

  9. 当院におけるMDSの移植成績について

    永田 安伸, 小林 武, 葉名尻 良, 菊池 拓, 名島 悠峰, 櫻井 千裕, 武藤 秀治, 山本 正英, 山下 卓也, 大橋 一輝, 秋山 秀樹, 坂巻 壽

    臨床血液  2008.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2008.9

    Language:Japanese  

  10. 移植前治療における静注ブスルファン(iv Bu)と経口ブスルファン(Bu)の移植成績についての後方視的検討

    菊池 拓, 山下 卓也, 葉名尻 良, 永田 安伸, 名島 悠峰, 櫻井 千裕, 植木 俊充, 武藤 秀治, 山本 正英, 小林 武, 大橋 一輝, 秋山 秀樹, 坂巻 壽

    臨床血液  2008.9  (一社)日本血液学会-東京事務局

     More details

    Event date: 2008.9

    Language:Japanese  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. CRISPR screening of B-cell lymphoma to enhance CAR-T therapy

    Grant number:23K15323  2023.4 - 2026.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

      More details

    Authorship:Principal investigator 

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  2. Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells

    Grant number:20K17375  2020.4 - 2023.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )